Unprecedented high and durable MRD negativity in elderly patients with comorbidities.
ONCOLOGY
Fully funded by 
Content independently selected
-
ASCO 2019 — Venetoclax+obinutuzumab extends PFS in frontline CLL -
ASCO 2019 — Acalabrutinib+obinutuzumab delivers high response in CLL Durable MRD negativity in peripheral blood.
-
ASCO 2019 — Extended ibrutinib therapy maintains long-term advantage in CLL 6-year follow-up of the phase 3 RESONATE trial.
-
ASCO 2019 — Iomab-B shows benefit in phase 3 trial of refractory/relapsed AML 98% reduction in peripheral blasts at day 3.
-
ASCO 2019 — Gilteritinib tops salvage chemotherapy for FLT3+ relapsed/refractory AML ADMIRAL study shows survival benefit across major ITD3 comutations.
-
CML-CP: favorable outcomes in study patients following 1L ponatinib Many patients generally maintained or deepened response.
-
Childhood ALL: are high-dose methotrexate and asparaginase antagonistic? In vitro concerns may be minimized in vivo.
-
CML: survivors have increased risk of secondary malignancy Risk pronounced for select neoplasms.
-
CLL: acalabrutinib offers high response rate in ibrutinib-intolerant patients All patients achieved stable disease or better.
-
FDA approves venetoclax-obinutuzumab for frontline CLL, SLL Approval realizes a chemo-free, fixed-duration treatment option.
-
AML: can cytokines be leveraged to treat cancer-related fatigue? Cytokines played a limited role in key endpoint changes.
-
Childhood ALL: late treatment effects evolving in survivors Could counseling and interventions require reassessment?
-
FDA approves ivosidenib for frontline IDH1-mutant AML More than 4 in 10 patients achieved CR+CRh.
-
CML-CP: considerations for patients discontinuing nilotinib Some adverse events increased following discontinuation.